ArticleBMJ open2026
Incidence and predictors of loss to follow-up after ART initiation at public health facilities in Sierra Leone (2020-2024): a retrospective cohort study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to estimate the incidence and predictors of loss to follow-up (LTFU) among adults after antiretroviral therapy (ART) initiation at five provincial referral hospitals in Sierra Leone.
designA facility-based retrospective cohort study.
settingThis study was conducted at five provincial government referral hospitals in Sierra Leone from January 2020 to December 2024. PARTICIPANT: HIV patients aged 15 and above who initiated ART between 1 January 2020, and 31 December 2020, and attended at least one follow-up visit at the five national referral hospitals. PRIMARY OUTCOME MEASURE: The primary outcome in this study was LTFU. LTFU was defined as absence from care, operationalised as no documented clinical encounter and/or ART refill for ≥90 days after the last expected clinical contact among patients not recorded as dead or transferred out.
resultsOf the 1544 patients (67.7% female), the median follow-up was 4.25 years (IQR not stated), totalling 5748.6 PY. Outcomes were 550 LTFU (35.6%), 853 in care (55.2%), 64 (4.1%) transferred and 77 (5.0%) died. The LTFU incidence was 9.57 per 100 PY (95% CI 8.78 to 10.37). Multivariable analyses revealed several factors significantly associated with higher LTFU: lack of tuberculosis (TB) screening (HR=4.47; 95% CI 3.66 to 5.46), WHO stage III/IV (HR=1.51; 95% CI 1.20 to 1.89), no regimen change (HR=5.12; 95% CI 2.39 to 11.00), non-disclosure of HIV status (HR=1.63; 95% CI 1.19 to 2.25), underweight body mass index (BMI) at follow-up (HR=1.37; 95% CI 1.05 to 1.78) and residence in the Southern (HR=1.97; 95% CI 1.57 to 2.48) or Eastern region (HR=2.13; 95% CI 1.49 to 3.03). Conversely, rural residence was associated with lower LTFU (HR=0.58; 95% CI 0.43 to 0.79).
conclusionThe study found a substantial incidence of LTFU. Risk factors of LTFU were gaps in TB screening, advanced clinical stage, absence of timely regimen adjustments, non-disclosure, low BMI and regional disparities. Strengthening integrated TB/HIV services, nutritional support, disclosure-enabling counselling and region-specific retention strategies, especially in urban, Southern and Eastern areas, may improve retention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.